NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

半年間の収益性: -90.84%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Verrica Pharmaceuticals Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

さらに詳しく
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 5.32
1日あたりの価格変動: +5.39% (0.649)
週ごとの価格変動: -1.44% (0.694)
月ごとの料金変更: -44.84% (1.24)
3ヶ月間の価格変動: -59.53% (1.69)
半年間の価格変動: -90.84% (7.47)
年間の価格変動: -90.66% (7.32)
3年間の価格推移: -92.58% (9.22)
5年間の価格推移: -95.78% (16.2)
10年間の価格推移: 0% (0.684)
年初からの価格変動: -38.38% (1.11)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
合計: 2.75

効率

名前 意味 学年
ROA, % -82.1 0
ROE, % -338.99 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.6985 10
合計: 7.8

成長の衝動

名前 意味 学年
収益性 Revenue, % -57.3 0
収益性 Ebitda, % 106.63 10
収益性 EPS, % 40.72 6
合計: 6.2
さらに詳しく

機関 音量 共有, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4

ETF 共有, % 年間の利益率, % 配当金, %
Invesco Dorsey Wright SmallCap Momentum ETF 0.07518 33.91 0.61241
iShares Micro-Cap ETF 0.00867 17.09 1.54048
iShares Russell 2000 Growth ETF 0.0017 38.04 0.6026
ProShares UltraPro Russell2000 0.00074 89.82 1.47873
ProShares Hedge Replication ETF 0.00022 5.92 1.47892
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



スーパーバイザー 役職 支払い 生年
Mr. Ted White President, CEO & Director 772.77k 1965 (60 年)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 年)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 年)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

住所: United States, West Chester. PA, 44 West Gay Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.verrica.com